Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024
30 Outubro 2024 - 5:05PM
Business Wire
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the
Company) today announced that it will release financial and
operational results for the third quarter of 2024 before markets
open on November 7, 2024.
Aurinia’s management team will host a conference call and
webcast at 8:30 am ET that day to review these results and provide
a general business update.
Webcast & Conference Call Details
The link to the audio webcast is available here. To join the
conference call, please dial (800) 715-9871 / +1 (646) 307-1963.
Conference ID: 6251719 or company name required for entry. A replay
of the webcast will be available on Aurinia’s website.
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical
company focused on delivering therapies to people living with
autoimmune diseases with high unmet medical needs. In January 2021,
the Company introduced LUPKYNIS® (voclosporin), the first
FDA-approved oral therapy dedicated to the treatment of adult
patients with active lupus nephritis. Aurinia is also developing
AUR200, a differentiated, potential best-in-class therapy for
autoimmune diseases that targets both BAFF (B-cell Activating
Factor) and APRIL (A Proliferation-Inducing Ligand).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241030222492/en/
Media & Investor Inquiries: Andrea Christopher
Corporate Communications & Investor Relations Aurinia
Pharmaceuticals Inc. achristopher@auriniapharma.com
General Investor Inquiries: ir@auriniapharma.com
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024
